Drug Type Small molecule drug |
Synonyms Doramapimod (USAN/INN), BIBR 796, BIBR-796 + [6] |
Target |
Mechanism p38 MAPK inhibitors(P38 mitogen-activated protein kinase inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC31H37N5O3 |
InChIKeyMVCOAUNKQVWQHZ-UHFFFAOYSA-N |
CAS Registry285983-48-4 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Psoriasis | Phase 3 | US | - | |
Psoriasis | Phase 3 | - | - | |
Crohn Disease | Phase 2 | - | 01 Oct 2001 | |
Plaque psoriasis | Phase 2 | - | 01 Jun 2001 | |
Rheumatoid Arthritis | Phase 2 | - | 01 May 2001 | |
Endotoxin Hyporesponsiveness | Phase 1 | - | 01 Feb 2000 | |
Neoplasms | Preclinical | US | - |
Not Applicable | - | 24 | BIRB 796 BS 20 mg | vvhewfjhoc(kmbtgrhuof) = reversible rise in ALT mhnsyvkftj (lxfmbqweoz ) View more | Positive | 01 Mar 2002 | |
BIRB 796 BS 50 mg | |||||||
Not Applicable | - | - | uexsavnzuv(reradifbft) = mild, reversible, clinically non-significant rise lzknwiqqco (znjdnpcxap ) View more | Positive | 01 Mar 2002 |